Full-Dose Psilocybin Therapy: How It Differs from Microdosing

Q1: When reports say "psilocybin beat antidepressants in a trial" — does that apply to microdosing?

No. Reports like this refer to the Carhart-Harris et al. 2021 trial that compared full-dose psilocybin therapy — 25mg, clinically supervised, with trained therapist support throughout — against escitalopram (an SSRI) for major depressive disorder. Microdosing played no part in that study. Applying those findings to microdosing is a category error. The two practices share a molecule but do not share an evidence base, a dose range, a mechanism of action, or an appropriate clinical population. Any claim that microdosing "beats antidepressants" based on clinical trial data is a significant misrepresentation of what the research actually shows.

Q2: Is full-dose therapy better than microdosing for depression?

For clinically significant depression — particularly severe or treatment-resistant presentations — the evidence strongly favours full-dose therapy. It has Phase 2 and 3 clinical trial data, rapid onset of antidepressant effect often within days of a session, and a mechanistic rationale well-characterised in human neuroimaging research. Microdosing for depression has observational data showing mood improvement, but no controlled trials and no evidence for severe or treatment-resistant presentations. Whether one is "better" depends on the severity of the depression, what is accessible to you, and whether the full-dose experience is something you are psychologically prepared and appropriate for.

​

Q3: Can microdosing eventually produce the same effects as a full dose session?

Not in the same way, and probably not at all in the ways that matter most for full-dose therapy's effects. Full-dose psilocybin therapy produces its results partly through the acute experience itself — the disruption of the default mode network, the emotional intensity, the often described mystical or peak experience — and partly through the neuroplasticity window that follows. These are not effects that accumulate gradually from repeated sub-perceptual doses. They require the intensity of a full-dose experience to initiate. Microdosing may produce modest cumulative effects through a related but different mechanism, but these differ fundamentally in kind and magnitude from the profound single-session therapeutic shift that full-dose therapy reliably produces.

Q4: Is it safe to microdose and also undergo full-dose therapy?

Combining the two requires careful coordination and should only be done with professional guidance. If you are in an active microdosing cycle, tolerance buildup means a full-dose therapy session may produce significantly attenuated effects compared to a fully rested baseline state — given the investment involved in clinical therapy, timing matters considerably. Most clinicians would advise completing a microdosing cycle, taking a full break to restore receptor sensitivity, and beginning fresh before a full-dose session. In the other direction, the integration period after a full-dose session is a neurologically sensitive window — introducing microdosing immediately before integration has consolidated adds unnecessary complexity. Discuss timing explicitly with any therapist or provider involved in either practice.

Q5: How do I access full-dose psilocybin therapy?

The most widely accessible legal routes are: clinical trial participation — search ClinicalTrials.gov for currently recruiting studies in your country, which are free, professionally supervised, and represent the highest available evidence standard; licensed psilocybin services in Oregon or Colorado in the United States, available to any adult without a diagnosis required; licensed psychiatric prescribing in Australia for treatment-resistant depression; or compassionate use programmes in Switzerland for severe conditions. Retreats operating in legally permissive jurisdictions such as the Netherlands, Jamaica, and Costa Rica offer legal full-dose experiences outside clinical frameworks, with variable quality of preparation and integration support. The quality of the support structure surrounding the experience matters enormously — not just the substance itself.

Q6: What makes full-dose therapy work — is it the drug or the therapy?

Both, and the interaction between them is essential — neither alone produces the full clinical effect. The drug creates a state of heightened neuroplasticity, profound emotional access, and disrupted default mode network activity. The therapy — preparation before the session and integration after — directs this state toward productive psychological work and helps translate the experience into lasting change. Clinical research consistently shows that therapeutic support quality is an independent predictor of outcomes, beyond pharmacology alone. A full-dose psilocybin experience without skilled therapeutic support produces less reliable and sometimes more problematic outcomes than the same experience within a proper therapeutic container. This is why full-dose therapy cannot be meaningfully separated into its drug component and its therapy component — they are a unified treatment that depends on both.

Q7: Is microdosing a stepping stone to full-dose therapy?

Not necessarily, though some people approach it that way and some psychedelic-informed therapists use microdosing protocols as part of preparation for full-dose sessions with particularly anxious patients. Microdosing can familiarise someone with psilocybin's general character, reduce anxiety about the full experience, and provide a lower-intensity entry into intentional psychedelic practice. However, the two are distinct practices with distinct goals — microdosing is not simply a lower-intensity version of full-dose therapy that naturally builds toward it. Many people microdose with no intention of ever pursuing full-dose therapy, and many people who pursue clinical therapy have never microdosed. The decision to pursue full-dose therapy, if accessible, should be made on its own terms — based on severity of need, readiness, and appropriate support — not as a linear progression from microdosing.